FOSUN PHARMA announced that its holding subsidiary HENLIUS has signed a "Cooperation and Licensing Agreement" with Palleon. The two parties will collaborate on the global development of Palleon's investigational product E-602 and related combination treatment plans in the field (for the treatment of human diseases) based on their respective patents and proprietary technologies, as well as the commercialization in their respective licensed regions. E-602 is a sialic acid enzyme fusion protein intended for the treatment of tumors and autoimmune diseases.